ClinicalTrials.Veeva

Menu
N

Nucleus Network | Nucleus Network - Melbourne, Australia

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tislelizumab
GS-9411
Tricaprilin
GC4711
ARC-520
NNZ-2566
mRNA-0184
Ustekinumab
iN1011-N17
ISM5411

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 95 total trials
Status recently updated

A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.

A Clinical Trial to Assess Pharmacokinetic Profiles and Safety of IVL3003

Enrolling
Active, not recruiting
Alzheimer Disease
Drug: Aricept Tablet
Drug: IVL3003

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Si...

Invitation-only
Alzheimer Disease
Healthy
Drug: VG-3927
Drug: Placebo

The purpose of this study is to evaluate the relative bioavailability of capsule and tablet formulations of TYRA-300-B01, and to evaluate the safety,...

Enrolling
Healthy
Drug: TYRA-300-B01

A Phase 1 study will assess the safety, tolerability, and pharmacokinetics of Atorvo+™ in healthy adult participants..

Not yet enrolling
Coronary Heart Disease
Dyslipidemias
Drug: Atorvo+™ +CBD (Arm 3)
Drug: Atorvo+™ +CBD (Arm 2)

This is an open-label, two-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-A1811 and preliminary anti-tum...

Active, not recruiting
Advanced Solid Tumors
Drug: SHR-A1811

This is a phase 1, randomized, First in Human (FIH), double-blinded, placebo-controlled study to assess the safety, tolerability, and PK of RSN0402 i...

Enrolling
Idiopathic Pulmonary Fibrosis
Lung; Disease, Interstitial, With Fibrosis
Drug: Placebo
Drug: RSN0402 Part 2

The purpose of this study is to test the safety of mRNA-0184 in healthy participants.

Enrolling
Healthy Participants
Drug: mRNA-0184

The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanc...

Active, not recruiting
Advanced Solid Tumor
Non Small Cell Lung Cancer
Drug: BGB-A445
Drug: tislelizumab

The purpose of this study is to evaluate the safety and tolerability of intravenously (IV) administered mRNA-0184 at 2 different infusion durations.

Enrolling
Healthy Participants
Drug: mRNA-0184

Trial sponsors

BeiGene logo
Gilead Sciences logo
Arrowhead Pharmaceuticals logo
R
C
G
I
Moderna logo
M
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems